IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: McTigue et al.

Art Unit: NOT YET ASSIGNED

Serial No. NOT YET ASSIGNED

Examiner: NOT YET ASSIGNED

Filed: August 28, 3001

Atty. Docket: 0125-0016D2

For: Modifications of VEGF Receptor-2 Protein

and Method of Use

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Prior to examination of the above-identified application, Applicant herewith respectfully requests the following amendments:

IN THE CLAIMS:

Kindly delete claims 1-16 and replace with the following claims 17-27.

- 17. A method for identifying compounds which interact with the kinase domain of a modified RTK polypeptide comprising the steps of:
 - (a) expressing in a host cell an isolated DNA sequence or variant thereof which encodes a modified RTK gene construct, wherein said RTK gene construct contains an RTK kinase domain α helix D linked to RTK kinase domain α helix E by a truncated RTK kinase insert domain (KID), said host cell capable of producing a modified RTK polypetide that retains kinase activity and is suitable for x-ray crystallography; and
 - (b) exposing said modified RTK polypeptide to said compound; and
 - evaluating the interaction between the kinase domain of said modified RTK polypeptide and said compound.

- 18. The method of claim 17, which further comprises:
 - (d) conducting said x-ray crystallography on said modified RTK polypeptide.
- 19. The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of the highly charged residues from the KID.
- 20. The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of 50 residues from the KID.
- 21. The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of 60 residues from the KID.
- 22. The method of claim 17 wherein said truncated kinase domain linking said helix D to said α helix E is of a sufficient length so as to allow said helices to maintain conformation associated with kinase structure.
- 23. The method of claim 17 wherein said RTK polypeptide is a member of the PDGFR family.
- 24. The method of claim 23 wherein said PDGFR member is selected from the group consisting of VEGFR-1, VEGFR-2, PDGFR-α, PDGFR-β, stem cell growth factor receptor (c-kit), and colony stimulating factor-1 receptor (CSF-1R/c-fms).
- 25. The method of claim 17 wherein said RTK polypeptide is selected from the group consisting of insulin receptor (IRK), fibroblast growth factor receptor-1 (FGFR-1), and VEGFR-2.
- 26. The method of claim 17 wherein said RTK polypeptide is VEGFR-2.
- 27. The method of claim 17 wherein said modified RTK polypeptide comprises the VEGFR2Δ50 polypeptide of SEQ ID NO: 5.

REMARKS

It is respectfully requested that the Examiner enter these amendments prior to examining the application on its merits.

Respectfully submitted,

SHANKS & HERBERT

y: Shelly Guest Cermak

Reg. No. 39,571

Date: 8-28-01

TransPotomac Plaza 1033 N. Fairfax Street Suite 306 Alexandria, VA 22314 (703) 683-3600